Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Walton

Showing results (191-200 of 199) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 199 results.
Molecular Oncology|October 25, 2017
Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitorSteven R Whittaker, Clare Barlow, Mathew P Martin, et al.
Journal of Medicinal Chemistry|February 20, 2019
Binding to an Unusual Inactive Kinase Conformation by Highly Selective Inhibitors of Inositol-Requiring Enzyme 1α Kinase-EndoribonucleaseGiampiero Colombano, John J Caldwell, Thomas P Matthews, et al.
Molecular Cancer Therapeutics|December 31, 2010
Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930Timothy A Yap, Mike I Walton, Lisa-Jane K Hunter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 30, 2012
CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugsMike I Walton, Paul D Eve, Angela Hayes, et al.
Oncotarget|August 22, 2015
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphomaMike I Walton, Paul D Eve, Angela Hayes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2025
Correction: AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor ActivityTimothy A Yap, Mike I Walton, Kyla M Grimshaw, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2012
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activityTimothy A Yap, Mike I Walton, Kyla M Grimshaw, et al.
Journal of Medicinal Chemistry|November 25, 2011
Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphingJohn C Reader, Thomas P Matthews, Suki Klair, et al.
Journal of Medicinal Chemistry|May 12, 2016
Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)James D Osborne, Thomas P Matthews, Tatiana McHardy, et al.
Pageof 20

Showing results (191-200 of 199) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 199 results.
Molecular Oncology|October 25, 2017
Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitorSteven R Whittaker, Clare Barlow, Mathew P Martin, et al.
Journal of Medicinal Chemistry|February 20, 2019
Binding to an Unusual Inactive Kinase Conformation by Highly Selective Inhibitors of Inositol-Requiring Enzyme 1α Kinase-EndoribonucleaseGiampiero Colombano, John J Caldwell, Thomas P Matthews, et al.
Molecular Cancer Therapeutics|December 31, 2010
Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930Timothy A Yap, Mike I Walton, Lisa-Jane K Hunter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 30, 2012
CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugsMike I Walton, Paul D Eve, Angela Hayes, et al.
Oncotarget|August 22, 2015
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphomaMike I Walton, Paul D Eve, Angela Hayes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2025
Correction: AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor ActivityTimothy A Yap, Mike I Walton, Kyla M Grimshaw, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2012
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activityTimothy A Yap, Mike I Walton, Kyla M Grimshaw, et al.
Journal of Medicinal Chemistry|November 25, 2011
Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphingJohn C Reader, Thomas P Matthews, Suki Klair, et al.
Journal of Medicinal Chemistry|May 12, 2016
Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)James D Osborne, Thomas P Matthews, Tatiana McHardy, et al.
Pageof 20